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Abstract
Background: The plasminogen activator inhibitor-1 (PAI-1) spontaneously converts from an
inhibitory into a latent form. Specificity of PAI-1 is mainly determined by its reactive site (Arg346-
Met347), which interacts with serine residue of tissue-type plasminogen activator (tPA) with
concomitant formation of SDS-stable complex. Other sites may also play roles in determining the
specificity of PAI-1 toward serine proteases.
Results: To understand more about the role of distal hinge for PAI-1 specificities towards serine
proteases and for its conformational transition, wild type PAI-1 and its mutants were expressed in
baculovirus system. WtPAI-1 was found to be about 12 fold more active than the fibrosarcoma PAI-
1. Single site mutants within the Asp355-Arg356-Pro357 segment of PAI-1 yield guanidine
activatable inhibitors (a) that can still form SDS stable complexes with tPA and urokinase
plasminogen activator (uPA), and (b) that have inhibition rate constants towards plasminogen
activators which resemble those of the fibrosarcoma inhibitor. More importantly, latency
conversion rate of these mutants was found to be ~3–4 fold faster than that of wtPAI-1. We also
tested if Glu351 is important for serine protease specificity. The functional stability of wtPAI-1,
Glu351Ala, Glu351Arg was about 18 ± 5, 90 ± 8 and 14 ± 3 minutes, respectively, which correlated
well with both their corresponding specific activities (84 ± 15 U/ug, 112 ± 18 U/ug and 68 ± 9 U/
ug, respectively) and amount of SDS-stable complex formed with tPA after denatured by
Guanidine-HCl and dialyzed against 50 mM sodium acetate at 4°C. The second-order rate
constants of inhibition for uPA, plasmin and thrombin by Glu351Ala and Glu351Arg were increased
about 2–10 folds compared to wtPAI-1, but there was no change for tPA.
Conclusion: The Asp355-Pro357 segment and Glu351 in distal hinge are involved in maintaining
the inhibitory conformation of PAI-1. Glu351 is a specificity determinant of PAI-1 toward uPA,
plasmin and thrombin, but not for tPA.
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Background
Plasminogen activator inhibitor-1 (PAI-1) is a serine pro-
teinase inhibitor in the serpin superfamily [1–3]. This 50
kDa glycoprotein is apparently the most important physi-
ological inhibitor of tissue-type plasminogen activator
(tPA) and of urokinase plasminogen activator (uPA).[4] It
was shown to play a crucial role in the regulation of vas-
cular thrombosis, tumor invasion, neovascularization,
inflammation and wound healing.[5,6] Increased plasma
levels of PAI-1 were found to be correlated with an
increased risk for cardiovascular diseases. [6–8] The essen-
tial function of PAI-1 in the fibrinolytic system has been
confirmed by studies with transgenic animals.[7,9]
PAI-1 shares a 35% homology with 40 other serpins.[10]
The X-ray structure of active PAI-1 [11,12] consists of three
sheets (A-C), nine helices (a-i) and a reactive center loop
(RCL). The RCL contains the residues Ser331 to Arg356
(P16-P10'), and within it there is a peptide loop (Glu 351
to Pro 357, P5'-P11'), which is defined as the distal hinge
(Table 1). It should be noted that the placement and con-
formation of the RCL in active PAI-1 is quite different
from that of latent PAI-1.[13] The movement of the distal
hinge and the insertion of the RCL into sheet A as strand
4A (s4A) should take place during the transition from the
active into the latent form of PAI-1.
The catalytic center of tPA interacts with the reactive site of
PAI-1 with concominant formation of 1:1 molar, SDS-sta-
ble complex. The P1 (Arg346) residue in the RCL of PAI-1
is an essential determinant for its target specificity and
inhibitory activity.[14,15] Since many serpins with identi-
cal amino acid residue at P1 position display different spe-
cificities, it is unlikely that the P1 residue is the sole
determinant for target protease specificity, other regions
of PAI-1 may also affect its specificity toward target pro-
teases. The variable region in serine proteases domain
determines their specificity for PAI-1. Alignment of varia-
ble region 1 of the serine proteases shows a remarkable
correlation between the composition of this area and their
susceptibility to inhibition by PAI-1 as shown in Table
2.[16] Both tPA and uPA, the target proteases of PAI-1,
contain a relatively extensive variable region 1, consisting
of four to five positively charged amino acid residues
present at identical position. Plasmin and thrombin with
moderate reactivity toward PAI-1 have relatively short var-
iable regions which contain only two to three positively
charged residues. For example, positively charged amino
acids in the variable region of tPA, uPA and thrombin play
dominant roles in the specific interaction with PAI-1.[17–
19] Furthermore, Glu350 (P4') of PAI-1 has been shown
to mediate the interactions with tPA.[18]
In this study, By producing wtPAI-1 and several single site
mutations in the distal hinge of PAI-1 in a baculovirus
expression system, we were able to find out the role of the
distal hinge in conformational transition of PAI-1 and to
elucidate the role of Glu351 in PAI-1 for serine protease
specificities.
Results
Characterization of wtPAI-1
To confirm the validity of recombinant PAI-1 as a model
to study the native inhibitor secreted from human fibrosa-
rcoma cells, we compared the recombinant PAI-1 and the
fibrosarcoma PAI-1 first by SDS-PAGE and immunoblot
with anti-PAI-1 monoclonal antibodies. The molecular
weight of wtPAI-1 was found to be lower than native PAI-
1 (~50 kDa, Fig. 1B). We assumed that this is due to a
lower (probably different) extent of glycosylation in the
baculovirus expression system. Indeed, when both pro-
teins were deglycosylated with N-glycanase they were
found to have an essentially identical M.W. (~48 kDa)
and to cross-react immunochemically (Fig. 1B). Further-
more, when this wtPAI-1 was chromatographed on
heparin-Sepharose it was found to be > 98% pure by silver
staining of the gel (Fig. 1A lane 2).
Interestingly, the specific inhibitory activity of wtPAI was
63 ± 15 U/ug just after purification, and was increased to
84 ± 21 U/ug after denatured by 6 M Gdn-HCl and
refolded in 50 mM sodium acetate (pH 5.6) at 4°C. In
contrast, the specific activity of the fibrosarcoma PAI-1
was only 5 ± 3 U/ug before activation, and was only
increased to 45 ± 16 U/µg after denaturing and refolding.
The high specific inhibitory activity of wt-PAI-1 could be
due to the fact that it was secreted from insect High-5 cells
cultured at 27°C, while the fibrosarcoma preparation of
PAI-1 was obtained from the medium of fibrosarcoma
cells cultured at 37°C [20]. Exposure to the higher tem-
perature could accelerate the conversion of the inhibitor
into its latent form.
The functional stability of wtPAI-1 and the fibrosarcoma
PAI-1 in the absence or in presence of vitronectin are illus-
trated in Figure 1C. wtPAI-1 lost its inhibitory activity at
the same pace as the fibrosarcoma PAI-1, indicating that
its functional half life as an inhibitor and its ability to be
stabilized by vitronectin are similar to those of the fibro-
sarcoma PAI-1.
The second-order rate constants (in M-1s-1 units) of the fib-
rosarcoma PAI-1 and the wtPAI-1 towards t-PA were 1.4 ±
0.5 × 107 and 1.7 ± 0.6 × 107, and towards uPA were 4.1 ±
1.4 × 107 and 4.4 ± 1.6 × 107, respectively. These results
show that the wtPAI-1 could inhibit tPA or uPA at the
same rate as the fibrosarcoma PAI-1. In addition, it is
known that PAI-1 inhibits either tPA or uPA by forming a
1:1 SDS stable complex [4], wtPAI-1 indeed could formBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
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Purification and characterization of wtPAI-1 Figure 1
Purification and characterization of wtPAI-1. Panel A, Purification of wtPAI-1. The medium from High five cells was harvested 
48 hours post infection and PAI-1s were purified on a heparin-Sepharose column and stained as described under Methods. 
Lane 1, the medium from infected High five cells, lane 2, wtPAI-1 eluted from the heparin-Sepharose column. Panel B, Treat-
ment of fibrosarcoma- and wtPAI-1 with N-glycanase as described under Methods. Lane1 and 2 were fibrosarcoma PAI-1, lane 
3, and 4 were wtPAI-1. Fibrosarcoma PAI-1 (lane 2) and wtPAI-1 (lane 4) were treated with N-glycanase. Panel C, Stability of 
fibrosarcoma PAI-1 or of wtPAI-1. Fibrosarcoma PAI-1 or wtPAI-1 was incubated (37°C) in the absence (empty circle and 
square) or in the presence of a two molar fold of vitronectin (filled circle and square) in PBS. At the indicated time periods, 
aliquots were removed and the inhibitory activity of the PAI-1s towards uPA was measured as described under Methods. The 
inhibitory activity prior to the incubation at 37°C was taken as 100%.
A                          BBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
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SDS stable complex with tPA or uPA (Fig. 3A) just as fib-
rosarcoma PAI-1.
Single site mutations within the distal hinge of PAI-1
Since a proline occurs not only in position 357 of PAI-1,
but also in the corresponding position of several other ser-
pins (Table 1) we attempted to find out how does a muta-
tion of P357 affect the inhibitory activity of PAI-1. Mutant
of Pro357Gly blocked the inhibitory activity of PAI-1 (Fig.
2A). Similarly, a mutation into proline of either Asp355 or
Arg356 also inactivated the inhibitor. It should be noted
that all these mutants could be activated to a similar
extent by 6 M Gnd-HCl (~20% inhibitory activity of the
wtPAI-1, activated under the same conditions). These
results suggest that a single site mutation at either one of
the positions 355, 356 or 357 significantly inactivates
PAI-1.
To elucidate the mechanism through which such muta-
tions affect the activity of PAI-1, we determined their
effect on the functional stability of PAI-1 and on its ability
to form an SDS stable complex with either tPA or uPA. As
seen in Fig. 2B, the rate of the spontaneous inactivation of
the inhibitor was significantly increased upon mutation:
the functional half life of the mutants Asp355Pro,
Arg356Pro and Pro357Gly was 23.8 ± 4.5 min, 26.2 ± 3.7
min and 24.7 ± 4.8 min, respectively, while that of wtPAI-
1 was 89.8 ± 8.7 min. Interestingly, there was no signifi-
cant difference between the mutants tested and the wtPAI-
1 in their ability to inactivate either tPA or uPA (Table 3).
They could also form SDS-stable complexes with tPA or
uPA just as well as wtPAI-1 (Fig. 3A).
An interesting structural similarity among several serpins
is known to occur at the position corresponding to 355 in
PAI-1. While in PAI-1 this position accommodates a neg-
atively charged aspartic acid residue, in other serpins it
sometimes accommodates its non charged analog aspar-
agine (Table 1). Asp355His, Asp355Lys, Asp355Glu,
Asp355Gln and Asp355Asn were prepared and used to
show that the negatively charged aspartic acid in PAI-1 is
essential (though not sufficient) for its inhibitory activity.
Mutation of Asp355 by asparagine (the non charged ana-
log of aspartic acid), or by histidine or lysine (that have a
positively charged side chain) or by alanine (neutral),
inactivated PAI-1. Replacement of this aspartic acid resi-
due even by the negatively charged glutamic acid (a very
close analog of aspartic acid) did not significantly suffice
to restore a full inhibitory activity of PAI-1 (Fig. 3B). After
activation with 6 M Gnd-HCl, each of the six mutants
exhibited a relatively high inhibitory activity, but their
specific activities were still much lower than that of wtPAI-
1 (Fig. 3B). Among them, Asp355Lys (5.1 ± 4.1 U/ug) had
the lowest specific activity, while the Asp355Asn (20 ± 4.2
U/µg) had the highest specific activity (Fig. 3B). Although
they had lower specific activities, all of the mutants men-
tioned above could still form SDS-stable complexes with
tPA or uPA just as the wtPAI-1 (data not shown).
Table 1: Amino acid sequence alignment at the carboxyl-terminal edges of various serpins
s1C      s4B       s5B
PAI-1 EIIMDRPFLFVVRHNPTGTVLFMGQVMEP
Antitrypsin EVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK
Antithrombin TFKANRPFLVFIREVPLNTIIFMGRVANPCVK
Antichymotrypsin IVRFNRPFLMIIVPTDTQNIFFMSKVTNPKQA
Ovalbumin EFRADHPFLFCIKHIATNAVLFFGRCVSP
Antiplasmin SFSVNRPFLFFIFEDTTGLPLFVGSVRNPNSAPREL
Table 2: Comparison of variable region of protease domain in serine proteases
Protease Constant region 1 Variable region Constant region 2
tPA PWQAAI FAKHRRSPGERF LCGG
uPA PWFAAI YRRHRGGSVTY VCGG
Plasmin PWQVSL RTRFGMH FCGG
Thrombin PWQVM FRKSPQEL LCGA
Alignments of the amino acids sequences of the first variable region and parts of the surrounding constant regions of the protease domain of tPA, 
uPA, plasmin and thrombin. In the variable region positively charged amino acid residues are underlined.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
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The specific inhibitory activity and functional stability of wtPAI-1, D355P, R356P and P357G Figure 2
The specific inhibitory activity and functional stability of wtPAI-1, D355P, R356P and P357G Panel A: The specific inhibitory 
activity of wtPAI-1, D355P, R356P and P357G towards uPA was measured immediately after their purification and after their 
activation with 6 M Gdn-HCl as described under Methods. The data represent the mean ± SEM of three separate determina-
tions. Panel B: wtPAI-1, D355P, R356P and P357G were incubated in PBS at 37°C. At the indicated time periods, aliquots were 
removed and the inhibitory activity of the PAI-1s towards uPA was measured as described under Methods. The inhibitory 
activity prior to the incubation at 37°C was taken as 100%.
A
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Complex formation and specific inhibitory activity of PAI-1s Figure 3
Complex formation and specific inhibitory activity of PAI-1s Panel A: The PAI-1s were incubated for 30 min at 37°C in the 
absence or in the presence of a two molar excess of either single-chain tPA or uPA. They were then subjected to SDS-PAGE 
and immunobloting using anti-PAI-1 monoclonal antibodies. Lanes 1, 4, 7, 10 are PAI-1s only, lanes 2, 5, 8, 11 are PAI-1s with 
tPA, and lanes 3, 6, 9, 12 are PAI-1s with uPA. The filled arrow indicates the complexes between PAI-1s and tPA, and the reg-
ular arrow indicates the complex between PAI-1s and uPA. Panel B: The specific inhibitory activity of D355A, D355H, D355K, 
D355E, D355Q, and D355N towards uPA was measured immediately after their purification and after their activation with 6 M 
Gdn-HCl as described under Methods. The data represent the mean ± SE of three separate determinations.
A
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Two additional mutations, Arg356Ala and Arg356Glu,
were prepared to further elucidate the role of Arg356. The
specific inhibitory activity of Arg356Ala was 7.2 ± 2.5 U/
µg, while Arg356Glu exhibited essentially no inhibitory
activity. This specific activity was increased to 35.4 ± 8.7
U/ug for Arg356Ala and 6.4 ± 2.3 U/µg for Arg356Glu
after denature and refolding. Just like ARG356Pro,
Arg356Ala and Arg356Glu were much more labile than
wtPAI-1. These results suggest that the role of the Asp355-
Pro357 segment is to stabilize the inhibitory conforma-
tion of PAI-1.
Specific activity, functional stability and complex 
formation of Glu351Ala and Glu351Arg
The specific inhibitory activities of wtPAI-1, Glu351Ala
and Glu351Arg were assessed with uPA and S-2444. As
shown in Fg. 4A, the specificity of wtPAI-1, Glu351Ala
and Glu351Arg after denatured by 6 M Gdn-HCl and dia-
lyzed against 50 mM sodium acetate, pH 5.6, was 84 ± 15,
112 ± 18 and 68 ± 9 U/ug, respectively. Glu351Ala had a
higher, and Glu351Arg lower specific activity than wtPAI-
1. The specific activities of PAI-1s determined immedi-
ately after purification displayed similar pattern as that of
inhibitors reactivated. There was about 15–20% increase
after reactivation compared to each untreated protein
itself. As shown in Fig. 4B, the two mutants also spontane-
ously lost their inhibitory activity(convert to latency) as
wtPAI-1, but at different rates. The functional stability of
wtPAI-1, Glu351Ala, Glu351Arg was about 18 ± 5, 90 ± 8
and 14 ± 3 minutes, respectively. It suggested that the spe-
cific activities measured above, to some extent, propor-
tionally represent the functional stability. More
importantly, amount complexes formed by tPA and PAI-
1s remained after incubation at 37°C (Fig. 4C) were pro-
portionally concordant with the results obtained from
enzymatic stability assay (Fig. 4B). This proves that results
from enzymatic assay are valid. The result of functional
stability suggests that Glu351 is indeed involved in the
conformational transition of PAI-1.
Inhibition of thrombin by PAI-1s and Neutralization of PAI-
1s by Thrombin
Both mutants inhibited thrombin more efficiently than
wtPAI-1, more importantly, Glu351Ala was better than
Glu351Arg in inhibiting thrombin (Fig. 5A); Inhibition of
thrombin by Glu351Arg was almost as same as by
Glu351Ala in presence of vitronectin (Fig. 5B), which
facilitated the thrombin inhibition by both mutants.
When excess equal amount of thrombin was incubated
with equal amount of PAI-1s in term of inhibitory activity
against uPA, mutant inhibitors were neutralized faster by
thrombin than wtPAI-1, and vitronectin also facilitated
the neutralization of Glu351Ala or Glu351Arg by
thrombin, just similar to the wtPAI-1 (Fig. 5C).
Inhibition of plasmin by PAI-1s
When plasmin was incubated with increased amount of
equal active PAI-1s in absence or in presence of vitronec-
tin, it was inhibited faster by mutants than by wtPAI-1
(Fig. 6 upper panel); and both of mutant also displayed
improved inhibition toward plasmin in presence of vit-
ronectin (Fig. 6 lower panel).
Kinetic analysis
The rate constants of tPA for wtPAI-1, Glu351Ala and
Glu351Arg were similar (Table 4), however, The rate con-
stants of inhibition toward uPA by Glu351Ala and
Glu351Arg were 4 and 7-fold higher than by wtPAI-1,
respectively. Moreover, The rate constants of Glu351Ala
and Glu351Arg for thrombin inhibition were 2 to 4 folds
higher than that of wtPAI-1 and rate constants of
Glu351Ala and Glu351Arg to plasmin were 2 fold higher
than that of wtPAI-1. This indicates that Glu351 is not
essential for the interaction with tPA, but it is an very
important determinant for the optimal interaction with
uPA, thrombin and plasmin.
Disscusion
The validity of human recombinant wtPAI-1 in represent-
ing the physiological form of the inhibitor is shown here
by the following: (a) The inhibitory activity of this wtPAI-
1 is actually higher than the inhibitory activity of the PAI-
1 isolated from fibrosarcoma cells (12 fold more
Table 3: Second-order rate constants of wtPAI-1, D355P, R356P, P357G toward tPA or uPA.
tPA(M-1s-1)u P A ( M -1s-1)
wtPAI-1 1.7 ± 0.6 × 107 4.4 ± 1.6 × 107
D355P 2.0 ± 0.7 × 107 5.1 ± 1.7 × 107
R356P 1.3 ± 0.5 × 107 4.7 ± 1.7 × 107
P357G 1.6 ± 0.7 × 107 4.9 ± 2.5 × 107
The second-order rate constants of inhibition, expressed in M-1 s-1 were determined as described in the Materials and Methods section. Values are 
averages of at least four independent experiments.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
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Specific activity, functional stability an complex formation of E351A and E351R Figure 4
Specific activity, functional stability an complex formation of E351A and E351R Panel A, Specific activities of wtPAI-1 and 
mutants were measured by a direct chromogenic assay using uPA and substrate S-2444 in microtiter plate as described under 
Methods. One unit of PAI-1 activity is defined as the amount that completely neutralizes 1 U of u-PA. Panel B, wtPAI-1, or 
mutants in assay buffer were incubated at 37°C. At times indicated, aliquots were taken out and determined their activity 
immediately as described above. The specific activity obtained at time zero was assigned a value of 100%. Panel C, complex for-
mation of PAI-1s with tPA: certain amount of wtPAI-1, E351A and E351R were incubated with equal amount of tPA at 37°C for 
30 minutes before put on ice, at same time these PAI-1s were incubated in PBS at 37°C for 3 hrs, respectively, before they 
were incubated with same amount of tPA at 37°C for 30 minutes, then the protein samples prepared at two time points were 
subjected to SDS-PAGE, and probed the membrane blot with anti-PAI-1 monoclonal antibody. Lane1, 2 and 3 for wtPAI-1, 
E351A and E351R at zero time point, lane 4, 5, 6 for wtPAI-1, E351A and E351R after 3 hours' incubation at 37°C.
A
B
1         2         3           4       5       6
PAI-1-tPA 
complex
PAI-1
CBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
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Inhibition of thrombin by wtPAI-1, E351A and E351R and Neutralization of PAI-1s by thrombin Figure 5
Inhibition of thrombin by wtPAI-1, E351A and E351R and Neutralization of PAI-1s by thrombin Thrombin (50 ul, 0.5 U/ml) was 
incubated with equal amount of wtPAI-1, E351A, or E351R in term of inhibitory activity toward uPA (panel A), or in presence 
of vitronectin(panel B). After 20, 40, 60 and 120 min, remaining thrombin activities were determined with S-2238. The initial 
activity of thrombin was taken as 100%. Panel C, Forty nanomolar of thrombin were incubated with 10 nM of active PAI-1 
alone, or in presence of 40 nM vitronectin at 37°C. After 30 min, residual PAI-1 activity was determined by titration on uPA. 
The residual PAI-1 activity without incubation with thrombin was taken as 100%. Empty bars, PAI-1s, filled black bars, PAI-1s + 
thrombin, and filled light bars, PAI-1s + thrombin + vitronectin.
E351R
E351A
wtPAI-1
wtPAI-1+Vn
E351R+Vn
E351A+Vn
A
B
CBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
Page 10 of 15
(page number not for citation purposes)
Inhibition of plasmin by wtPAI-1, E351A and E351R Figure 6
Inhibition of plasmin by wtPAI-1, E351A and E351R Plasmin (50 ul, 100 nM) was incubated with equal amount of wtPAI-1, 
E351A, or E351R alone in term of inhibitory activity toward uPA (0, 0.32, 1.6 and 8 unit in 50 ul, respectively, upper panel), or 
in presence of two molar excess of vitronectin(lower panel). Residual plasmin activity was calculated according to the absorb-
ance at 405 nm after 60 minutes incubation with plasmin substrate (final concentration, 0.5 mM). The activity of plasmin with-
out PAI-1s was taken as 100%.
wtPAI-1
E351R
E351A
wtPAI-1+Vn
E351R+Vn
E351A+VnBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
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inhibitory prior to activation by 6 M Gnd HCl, and 2 fold
more inhibitory after activation); (b) The inhibition rates
of both tPA and uPA obtained with wtPAI-1 are essentially
identical to those obtained with PAI-1 secreted by fibrosa-
rcoma cells; (c) wtPAI-1 forms SDS-stable complexes with
tPA and uPA that are similar to those obtained with the
fibrosarcoma PAI-1; (d) The stabilization of the inhibitory
conformation of wtPAI-1 by vitronectin is essentially
identical to that of the fibrosarcoma PAI-1; (e) The molec-
ular weight of the protein moiety of wtPAI-1 is similar to
that of the fibrosarcoma PAI-1, if the two inhibitor prepa-
rations are deglycosylated with N-glycanase. In view of the
above, we used mutated recombinant PAI-1s to assess the
importance of specific amino acid residues in the inhibi-
tory function of PAI-1.
This study focuses on the functional role of Glu351,
Asp355, Arg356 and Pro357 within the distal hinge
region of PAI-1. We suspected that the "bending" property
of the prolyl residue at position 357 and the rigidity in the
polypeptide backbone imposed by prolyl residues in gen-
eral might have a role in maintaining the inhibitory con-
formation of this segment. Indeed, we found that a
mutant of Pro357 in which the proline residue was
replaced by glycine is non inhibitory. This mutant could,
however, be activated by 6 M Gdn-HCl, supporting the
notion that the lack of activity of Pro357Gly may indeed
be due to a conformational effect on the structure of the
inhibitor.
The structural importance of the local conformation of
the Asp355-Pro357 segment is further illustrated by two
single site mutants in which the original Pro357 was pre-
served, but an additional proline residue was introduced
(by mutation) at positions 355 or 356. These two mutants
were inactive but they were activated considerably by
treatment with 6 M Gdn-HCl. The enhanced lability of
these mutants was evident from a more rapid conversion
into their latent structure. These mutants were found to
form SDS-stable complexes with either tPA or uPA after
treatment with 6 M Gdn-HCl. This treatment presumably
allows them to restore (at least in part) their inhibitory
structure, and their ability to inhibit plasminogen activa-
tors with second order rate inhibition constants similar to
those obtained with the wtPAI-1. Since these mutants
have faster latency transition time, we assume that these
mutations do so by loosening the structural restrictions
normally imposed on the mobility of the RCL. [21] How-
ever, we show here that in spite of the fact that these
mutants are structurally more fragile, their second-order
rate constants towards their target proteinases are very
similar to those of wtPAI-1. This implies that a facilitated
latency transition does not necessarily result in slow rate
inhibition towards tPA or uPA. This is in line with the
findings that stable PAI-1 mutants (72-fold or 245-fold
longer half life than of wtPAI-1) have similar inhibition
rate constants towards uPA. [22,23] We therefore con-
clude that the segment Asp355-Pro357 is not involved
directly in the complex formation, but rather in the
latency transition.
The results presented here with the mutants expressed in
High 5 cells show that indeed the conversion of the nega-
tive into a positive charge (Asp355His and Asp355Lys)
yields an inactive inhibitor protein, but the preservation
of the negative charge does not suffice by itself. Mutation
of this aspartic acid residue into a negatively charged
glutamic acid (also negatively charged, and differs from
Asp355 by having an extra methylene group only) still
yields a mutant PAI-1 that has a very low inhibitory activ-
ity. The fact that the negative charge is an important factor
in the inhibitory activity is illustrated here by the finding
that Asp355Asn and Asp355Gln have both a very low
activity, yet they are more active than Asp355Lys and
Asp355His. Generally speaking, it is clear from our studies
that any mutation of Asp355, whether it preserves the neg-
ative charge or not, yields an inactive inhibitor.
The markedly enhanced functional stability of Glu351Ala
(Fig. 4B) may be due to the unfavorable interactions
resulted from Ala instead of Glu, which delays the latency
conversion, while the decreased functional stability of
Glu351Arg may be caused by positively charged Arg,
which may facilitate the conformation transition. Here we
show that different amino acid substitution at the same
position result in opposite effect on the PAI-1 stability,
Table 4: The second-order rate constants of wtPAI-1, E351A and E351R towards tPA, uPA, plasmin and thrombin.
tPA (107 M-1s-1) uPA (107 M-1s-1) Thrombin (103 M-1s-1) Plasmin (104 M-1s-1)
wtPAI-1 2.11 ± 0.83 0.48 ± 0.27 0.72 ± 0.31 3.10 ± 1.15
E351A 1.25 ± 0.49 2.64 ± 0.53 1.74 ± 0.35 6.29 ± 1.83
E351R 1.52 ± 0.35 3.62 ± 0.74 3.30 ± 0.42 7.12 ± 1.96
The second-order rate constants of inhibition, expressed in M-1 s-1 were determined as described in the Materials and Methods section. Values are 
averages of at least four independent experiments.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
Page 12 of 15
(page number not for citation purposes)
suggesting that the network in which Glu351 is involving
does provide PAI-1 stability. Moreover, the structural sta-
bilization needs not necessarily affect its mechanism of
reactive center loop insertion, but instead may occur
through subtle optimization of interactions. Indeed,
results of studies with other proteins have generally sup-
ported the notion that thermodynamic stabilization of a
protein is global. This is also consistent with studies of
mutant T4 lysozymes with multiple substitutions at one
position demonstrated a direct relationship between the
hydrophobicity of the substituted residue and the result-
ing increase in stability. [24]
Cognate protease specificity
Improvements in specificity of mutants for uPA indicates
that Glu351 involve in the interaction with uPA. To the
best of our knowledge, this is the first time that the specif-
icity of PAI-1 toward uPA is partially mediated by the neg-
atively charged residue located in the C-terminal of
cleavage site in PAI-1. The interaction of Glu351 with uPA
is much more important than that of Glu351 with tPA,
which is demonstrated by improved reactivity of Glu351
mutants toward uPA, but not toward tPA, showing that
tPA is not directly interact with Glu351 of PAI-1, whereas
Glu351 is necessary for the optimal interaction with uPA.
Our results are concordant with previous study, [25]
which suggests that serpin body-protease body interac-
tions play significant roles in determining serpin inhibi-
tory activity against target proteases.
Non-cognate protease
Substitution of Glu351 also altered the specificity toward
non-cognate proteases: plasmin and thrombin. Glu at 351
may provide steric hindrance that slows the rate of
thrombin or plasmin inhibition. Mutations at Glu351
may decrease the original repulsive interactions with vari-
able region of thrombin, which may slow the rate of
thrombin inhibition, or results in favorable interactions
that may not exist when wtPAI-1 react with thrombin. So,
both Glu351Arg and Glu351Arg are better thrombin
inhibitors than wtPAI-1. Similar results were observed for
plasmin. With single mutation at position Glu351, we
improved reactivity of PAI-1 to thrombin and plasmin
without significantly affecting its specificity to tPA. This
substantiates previous mutagenesis studies, which dem-
onstrated that repulsive interactions and/or lack of pro-
ductive electrostatic interactions between Glu39 and
Glu192 of thrombin and PAI-1 are responsible for the
slow reaction of thrombin with this serpin.[26] Further-
more, the rapid inhibition of plasmin requires a non-cov-
alent interaction between an amino-terminal site of
plasmin and a carboxyl-terminal on anti-plasmin, and a
second site outside the RCL of PAI-1 contributes to its spe-
cific interaction with proteases.[15,27] The specificity of
the two mutants toward thrombin and plasmin implicates
that Glu351 of PAI-1 is involved in its specificity toward
thrombin and plasmin.
Conclusion
Single site mutations within the segment Asp355-Arg356-
Pro357 of PAI-1 yield Gdn-HCl activatable inhibitors that
can still form SDS stable complexes with plasminogen
activators, with second order inhibition constants that are
similar to the native inhibitor. Interestingly, the conver-
sion of these mutants to latent forms was ~3–4 fold faster
than wtPAI-1, suggesting that the Asp355-Pro357 segment
is involved in maintaining the inhibitory conformation of
PAI-1. Glu351 contributes to the optimal functional sta-
bility of PAI-1 and participates its conformational stabil-
ity. More importantly, Glu351 of PAI-1 is a specificity
determinant for uPA, thrombin and plasmin, but not for
tPA.
Methods
The following materials were obtained from commercial
sources: native PAI-1, secreted into the cell culture
medium from human fibrosarcoma cell line HT 1080
(Biopool); single-chain tPA and two-chain tPA standard
(Biopool); uPA, plasmin and thrombin were from Calbi-
ochem; the chromogenic substrate for uPA, pGlu-Gly-Arg
p-Nitroanilide (S-2444), the chromogenic substrate for
tPA and H-D-Ile-Pro-Arg-pNA-2HCl (S-2288) from
Chromgenix AB, chromogenic substrate for thrombin, H-
D-Phe-pipecolyl-Arg-pNA(S-2238) and chromogenic sub-
strate for plasmin, N-p-Tosyl-Gly-Pro-Lys-p-Nitroanilide
from Sigma); heparin-Sepharose, monoclonal antibody
against PAI-1 from American Diagnostica, Inc.; recom-
binant N-glycanase (Genzyme diagnostics); the pRSET(A)
vector, baculovirus transfer vector pAcSG2 and Baculo-
Gold transfection kit from Pharmgen; Sf9 cells (Spodop-
tera frugiperda), High Five cell (Trichoplusia ni) from
Invitrogen; Restriction enzymes, T4  ligase and shrimp
phosphatase were purchased from New England Biolab.
BCA protein assay reagent from Pierce; A full-length cDNA
of human PAI-1 (pPAI-1-AI) [28] was generously pro-
vided by Prof. Keld Danö, The Finsen Laboratory.
General DNA techniques
Plasmid DNA was purified using either Promega or QIA-
GEN miniprep kits. The DNA was sequenced using the di-
deoxy chain termination reaction method using an ABI
373 DNA sequencer. Oligonucleotides were synthesized
using a 380 B DNA synthesizer (ABI model). DNA manip-
ulation techniques were carried out according to standard
procedures [29].
Construction of wtPAI-1 and its mutants
The pPAI-1-AI was digested with EcoRI and BglII to release
a 1426 basepair (bp) PAI-1 coding sequence, which was
isolated, purified, and ligated into EcoRI and BglIIBMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
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digested pVL1393. The resultant pVL1393-PAI-1 was ana-
lyzed by restriction mapping and sequencing. The
mutants at E351A, E351R, D355, R356, and P357 of PAI-
1 were generated by PCR. The occurrence of the resulting
mutations D355A, D355E, D355H, D355K, D355N,
D355P, D355Q, R356P, P357G as well as E351A and
E351R in pRSET was confirmed by sequencing. The PAI-1
sequence containing the desired mutations was digested
with EcoR1 and BglII, and then subcloned into pVL1393.
The recombinant baculoviruses containing either wtPAI-
1, or one of the above mutants was obtained as deccribed
by Kjoller et al. [30]
Expression and purification of wtPAI-1 and its mutants
High 5 cells, grown at 27°C in SF-900 serum-free
medium, were infected with high-titer virus stocks (1–3 ×
108/ml). The medium was collected 48 hrs after the infec-
tion (found to be the optimal harvesting time for wtPAI-
1) and then centrifuged for 5 minutes (125 × g). The
supernatents (50 ml) were collected and sodium chloride
(final concentration 0.25 M) was added. They were then
applied on a heparin-Sepharose column (bed volume 5
ml) that was equilibrated and run (flow rate 20 ml/h)
with a buffer consisted of 50 mM sodium acetate, pH 5.6,
containing 0.25 M NaCl and 0.01% Tween-20. The col-
umns were washed and the PAI-1s were eluted with a 40
ml gradient of 0.25 – 1 M NaCl in the same buffer.
SDS-PAGE, immunoblotting and deglycosylation of PAI-1
The medium of the infected cells and the elutent from
heparin-Sepharose were separated on 10% SDS-PAGE,
and monitored by silver staining. Fibrosarcoma PAI-1 and
wtPAI-1 were transferred onto nitrocellulose paper and
the proteins were revealed with anti-human PAI-1 mono-
clonal antibodies, followed by horseradish peroxidase
(HRP) conjugated rabbit anti-mouse antibody, and
enhanced chemiluminescence (ECL). 5 ug of Fibrosar-
coma PAI-1, or wtPAI-1 was denatured by boiling for 5
min in a buffer consisted of 0.5% SDS, 50 mM β-mercap-
toethanol and 50 mM Tris-HCl, pH 7.4. They were then
digested (18 hr, at 37°C) with 0.5 units of recombinant
N-glycanase in the presence of 2.5% NP-40, and subjected
to SDS-PAGE and silver staining. Protein concentrations
were determined by the Bio-Rad protein assay reagent.
Functional stability of fibrosarcoma PAI-1, wtPAI-1 and its 
mutants
The inhibitory activities of fibrosarcoma PAI-1, wtPAI-1,
and its mutants were measured by a direct chromogenic
assay using uPA (100 U/ug) and its substrate S-2444 in a
microtiter plate as described earlier [20]. Briefly, fibrosar-
coma PAI-1, wtPAI-1, or its mutants were diluted 1:10 in
the activity measuring assay buffer (50 uM Tris-HCl, pH
7.5, containing 0.15 M NaCl and 100 ug/ml BSA). The
PAI-1 samples were incubated in the absence or in the
presence of a two molar excess of vitronectin (the fibrosa-
rcoma PAI-1 and the wtPAI-1 were incubated with vit-
ronectin) at 37°C. At the times indicated, aliquots were
removed and analyzed immediately for their inhibitory
activity. One unit of PAI-1 activity is defined as the
amount that completely neutralizes 1 U of uPA. The spe-
cific activity obtained at time zero was assigned a value of
100%.
Activation of PAI-1 and kinetic analysis
Fibrosarcoma PAI-1, wtPAI-1 or its mutants were dena-
tured with 6 M guanidine-hydrochloride (Gdn-HCl) (45
min at 37°C), followed by dialysis (4–16 hours at 4°C)
against 50 mM sodium acetate, pH 5.6, containing 0.5 M
NaCl and 0.01% Tween-20. This process which PAI-1
regained its activity is called activation by Gdn-HCl. The
inhibitory activity of each of the PAI-1s was assayed
immediately. The second-order rate constants for the
interaction of the fibrosarcoma PAI-1, wtPAI-1 or the indi-
cated mutants with single-chain tPA or uPA were deter-
mined in a single-step assay as previously described. [20]
Specific activity, functional stability and complex 
formation of PAI-1s
The inhibitory activities of wtPAI-1 and mutants were
measured by a direct chromogenic assay using uPA (100
U/µg) and substrate S-2444. [17] Briefly, serially diluted
wtPAI-1, or mutants were incubated with equal volume of
uPA (50 µl, 50 U/ml) for 30 min at 37°C, followed by
addition of 100 µl, 0.5 mM S-2444. Residual uPA activity
was quantitated by measuring the change in absorbance at
405 nm with ELISA reader. The specific activity of PAI-1
was calculated based on the amount of uPA inhibited by
PAI-1. The assay for PAI-1 inhibitory activity toward two-
chain tPA was the same for uPA except that the samples
were incubated with tPA and S-2288. PAI-1 inhibitory
activity is expressed as the number of international units
of PAs inhibited by PAI-1. Specific activity of uPA and
two-chain tPA are 100 U/µg and 764 U/µg, respectively.
For the functional stability, wtPAI-1, or mutants were
incubated at 37°C. Aliquots were taken out at times indi-
cated and analyzed immediately as described above. The
specific activity obtained at time zero was assigned a value
of 100%. To provide the evidence to support the conclu-
sion obtained from enzyme assay, certain amount of
wtPAI-1, E351R and E351A were incubated with equal
amount of tPA at 37°C for 30 minutes before put on ice,
at same time these PAI-1s were incubated in PBS at 37°C
for 3 hours, respectively, before the PAI-1s were incubated
with same amount of tPA at 37°C for 30 minutes, then
the protein samples prepared at two time points were sub-
jected to SDS-PAGE and western blot as described before.BMC Biochemistry 2003, 4 http://www.biomedcentral.com/1471-2091/4/5
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Inhibition of thrombin and plasmin by PAI-1s
Thrombin (0.025 U), or plasmin (0.1 µg/ml) was incu-
bated at 37°C for 30 min with same amount of wtPAI-1,
E351A and E351R in term of inhibitory activity toward
uPA (20 U in the concentration range of 4–10 µg/ml) in
absence or presence of vitronectin (60 µg/ml). Linear
increase of absorbance at 405 nm were recorded after add-
ing S-2238 (final concentration 0.25 mM) for thrombin,
or N-p-Tosyl-Gly-Pro-Lys-p-Nitroanilide (final concentra-
tion 0.5 mM) for plasmin. Thrombin, or plasmin activity
without PAI-1 was taken as 100%.
Neutralization of PAI-1s by Thrombin
wtPAI-1 and mutants were incubated with four molar
excess of thrombin (40 nM) in the absence or presence of
vitronectin (30 nM). Control experiments were carried
out in the absence of thrombin. After 20 min at 37°C, the
activity of thrombin was quenched by the addition of
hirudin (final concentration, 60 units /ml), resulting in
inhibition of more than 95% of the amidolytic activity of
thrombin. Subsequently, the residual PAI-1 inhibitory
activity was determined by titration of aliquots on uPA,
using S2444 as substrate. The increase of the optical den-
sity at 405 nm in the samples was corrected for the values
measured with (hirudin-inactivated) thrombin alone,
since the amidolytic activity of thrombin on S2444 was
not completely blocked by hirudin,
Complex formation of PAI-1s with tPA or uPA
Complex formation of the fibrosarcoma PAI-1, wtPAI-1 or
its mutants with single-chain tPA or uPA were performed
as described earlier [20]. Samples of PAI-1s (5 U) were
incubated in the absence or in the presence of a 2-fold
excess of uPA or tPA in the activity assay buffer. Following
a 30 min incubation at room temperature, the samples
were subjected to a 10% SDS-PAGE and immunoblotting
as described above.
Abbreviations
tPA, tissue-type plasminogen activator; uPA, urokinase-
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